Anika Therapeutics vs Rxsight
Rxsight is the larger business, with $134m of revenue in fiscal 2025 against $113m for Anika Therapeutics (1.2 times as much). Rxsight grew faster (-3.9% against -5.9%). Anika Therapeutics kept more of each dollar of sales as profit: a net margin of -9.6% against -29.0%. Anika Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Anika TherapeuticsANIK, 2025 | RxsightRXST, 2025 |
|---|---|---|
| Revenue | $113m | $134m |
| Revenue growth | -5.9% | -3.9% |
| Net income | −$10.9m | −$38.9m |
| Operating margin | -9.8% | -35.8% |
| Net margin | -9.6% | -29.0% |
| Return on equity | -7.3% | -14.0% |
| Free cash flow | $4.4m | −$19.3m |
| Cash | $57.5m | $19.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $9.5m | — |
| Employees | 235 | 461 |
| Market value | $261m | $192m |
| Price vs our value range | — | — |
| Moat score | 53 (Moderate) | 27 (Weak) |
| Insider trades, 12 months | 4 buys, 0 sales | 0 buys, 4 sales |